Navigation Links
Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
Date:7/24/2009

ANN ARBOR, Mich., July 24 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS) announced that it has initiated a Phase II Clinical Trial for the Anaconda(TM) AAA (Abdominal Aortic Aneurysm) Stent Graft System in the U.S. The Anaconda system is manufactured by Scotland-based Terumo subsidiary Vascutek Ltd. The first U.S. implant was performed on June 8th at Arizona Heart Hospital by the principal investigator, Julio Rodriguez-Lopez, M.D.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )

The objective of the Vascutek Anaconda Stent Graft System Phase II IDE Study (G030036) is to assess the safety and effectiveness of the Anaconda stent graft system in patients presenting with AAA when compared to historical open surgical repair. The Food and Drug Administration (FDA) has given Terumo CVS approval to enroll 180 patients at 20 sites, some of which will be in Canada. The primary endpoint for the study is the successful treatment of the aneurysm twelve months after the implantation of the device. Patients in the study will be followed for a total of five years.

The Anaconda system is commercially available outside the U.S. where it has been implanted in nearly 4000 patients. It received CE Mark in Europe in April 2005.

According to the Society of Vascular Surgery, physicians diagnose approximately 200,000 people with AAAs in the U.S. annually. Treatment options include medical management of co-morbidities such as hypertension or pulmonary disease, open surgical repair and endovascular repair. Endovascular repair using commercially available devices has been associated with shorter recovery times, reduced hospital stay, and other benefits.


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
2. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
3. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
4. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
5. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
6. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
7. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
8. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 28 MedQuist Inc. (Nasdaq: MEDQ ... and a leader in technology-enabled clinical documentation workflow, ... (CAC) technology for improved coding productivity, efficiency, cost ... Spring, MedQuist vice president of Product Management, "CodeRunner ...
... Holdings, Inc. (OTC Bulletin Board: ADLS ... commercialization of novel drugs in the therapeutic areas of infection, ... million of proceeds from the exercise of the unit warrants ... 1, 2010. Each unit warrant entitled its holder to purchase ...
Cached Medicine Technology:MedQuist Introduces CodeRunner™ With Computer-Assisted Coding 2Advanced Life Sciences Receives $1.5 Million From Exercise of Unit Warrants and Secures Financing Commitment 2Advanced Life Sciences Receives $1.5 Million From Exercise of Unit Warrants and Secures Financing Commitment 3
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
(Date:1/22/2015)... is a famous dress online store for wedding dresses and ... collection of wedding dresses , and launches a site-wide women’s ... dress on your big day; the wedding gown is the ... to find the most suitable wedding dress. Now, we are ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... (NYSE Amex: FHC ) today announced that it ... Approval of the FC2 Female Condom(R) on Thursday, ... The Company announced its receipt of FDA approval for the ... today. Shareholders and other interested parties may participate in the ...
... a featured part of one of the fastest-growing ... HCPLive.com today announced a traffic- and revenue-sharing ... the most widely read physician blogs. KevinMD.com, home ... medical news, is written by Kevin Pho, MD, ...
... NEW YORK, March 11 JLL Patheon Holdings, LLC, an ... will be commencing its previously announced offer for any and ... Patheon Inc. ("Patheon") that it does not already own at ... Restricted Voting Share, which is equivalent to approximately C $2.57 ...
... Washington becomes 2nd state to legalize procedure , , ... suffering is the leading reason why terminally ill patients ... Act, according to an Oregon Health & Science University ... requested physician aid in dying or had contacted an ...
... Birner Dental Management Services, Inc. (Nasdaq: BDMS ... practices announced its regular quarterly dividend. The Company,s board ... cents per share of common stock. The dividend is ... 2009.Birner Dental Management Services, Inc. acquires, develops, and manages geographically ...
... pragmatic message of the "Food for Thought" podcast by ... 11 "If we don,t have time to be ... healthy" is how Colleen Patrick-Goudreau begins her 100th episode ... her signature combination of humor and wisdom to inspire ...
Cached Medicine News:Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 3Health News:KevinMD.com Joins the HCPLive.com Network 2Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 2Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 3Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 4Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 5Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 6Health News:Fear of Pain Drives Requests for Assisted Death 2Health News:'Life-Changing' Podcast Celebrates Its 100th Episode with Food for Thought on Eating Healthfully in a Recession 2
... information technology platform, the VERICIS Cardiovascular ... different sites (office, clinic, hospital) and ... angiography, echo, nuclear, MR, hemodynamics, reports, ... record on the cardiac patient. ...
... The compact UW7 Bidirectional Doppler has the operating ... LED's on the probe tip indicate the direction ... is also controlled on the probe tip. These ... control. ,The pencil style probe and cable are ...
... The first of an exciting new ... (Optical Low Coherence Reflectometry) technology,our Slitlamp-mounted* ... of 1m and this non-contact.,This ... at any time,and without concerns about ...
... graphic display and IOL power calculation software. ... include firmware module with SRKII, SRKT, Holladay ... tones increase in frequency the closer you ... alignment is achieved with corneal indentation. Triple ...
Medicine Products: